Acurx Pharmaceuticals (NASDAQ:ACXP) Raised to “Hold” at Wall Street Zen

Acurx Pharmaceuticals (NASDAQ:ACXP) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

ACXP has been the subject of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Acurx Pharmaceuticals in a report on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Acurx Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Stock Down 7.8%

Acurx Pharmaceuticals stock opened at $3.19 on Friday. Acurx Pharmaceuticals has a 52 week low of $3.17 and a 52 week high of $25.00. The business has a 50-day simple moving average of $4.50 and a 200 day simple moving average of $5.96. The stock has a market cap of $6.67 million, a price-to-earnings ratio of -0.37 and a beta of -1.25.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.38. On average, research analysts anticipate that Acurx Pharmaceuticals will post -0.89 earnings per share for the current year.

Institutional Trading of Acurx Pharmaceuticals

A hedge fund recently bought a new stake in Acurx Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 1,078,540 shares of the company’s stock, valued at approximately $551,000. Armistice Capital LLC owned 70.13% of Acurx Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).